Physician profile
Daniel J Paul
NPI 1699863340
$642.25
in general payments reported to CMS, 2019-2025
6 companies · $19.27 in 2025
The $19.27 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $316 · 2021: $46.95 · 2022: $11.86 · 2025: $19.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $430.21 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $75.88 | 2019 | |
| Abbvie INC. | $63.52 | 2019-2021 | |
| Novo Nordisk INC | $30.81 | 2019-2025 | |
| Lilly USA, LLC | $29.75 | 2020-2021 | |
| Eisai INC. | $12.08 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.